Skip to main content
[Preprint]. 2024 Sep 14:2024.09.11.611693. [Version 1] doi: 10.1101/2024.09.11.611693

Figure 1. FGF21 levels are elevated in the muscle and spinal cord tissues of ALS patients and the SOD1G93A mouse.

Figure 1

(A) FGF21 mRNA expression was analysed in normal (n = 24) and ALS (n = 36) muscle biopsy samples via RT-qPCR. **P = 0.004, unpaired two-tailed t-test with Welch’s correction. (B) FGF21 mRNA levels were quantified in normal (n = 7) and ALS (n = 11) post-mortem muscle samples (left panel) and FGF21 protein levels (n = 13 for normal samples; n = 18 for ALS samples; right panel). **P = 0.003, ****P < 0.0001, two-tailed Mann Whitney test. (C) FGF21 mRNA levels were quantified in normal (n = 14) and ALS (n = 22) post-mortem spinal cord samples (left panel) and FGF21 protein levels (n = 12 for normal samples; n = 18 for ALS samples; right panel). **P = 0.00, two-tailed Mann Whitney test. (D) Comparison of spinal cord and muscle FGF21 protein levels for 18 ALS patients. A spearman correlation test was used for analysis. (E) FGF21 mRNA levels in the gastrocnemius muscle (left panel) and spinal cord (right panel) were quantified across different age groups (20 – 150 days; n = 4–5 per group) from SOD1G93A mice and littermate controls. **P < 0.01, ***P < 0.001, ****P < 0.0001, unpaired two-tailed t-test comparing WT to SOD1G93A. For all graphs, error bars represent SD.